News
AVIR
3.930
-1.50%
-0.060
Atea Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 3d ago
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $8
Benzinga · 3d ago
Atea Pharmaceuticals price target raised to $8 from $7 at Morgan Stanley
TipRanks · 3d ago
Weekly Report: what happened at AVIR last week (1109-1113)?
Weekly Report · 4d ago
Atea Pharmaceuticals Earnings Call Highlights HCV Momentum
TipRanks · 5d ago
Atea Pharmaceuticals: A Clean DDI Profile And Shorter Treatment Duration Threaten Current Market Leaders
Seeking Alpha · 6d ago
Atea Q3 Loss Narrows On Lower Expenses; Hepatitis C Trial Data Due In Early 2027
NASDAQ · 11/10 14:37
Atea Pharmaceuticals, Inc. Reports Third Quarter 2026 Financial Results and Enters Credit Facility of Up to $200 Million
NASDAQ · 11/10 03:31
Atea Pharma (AVIR) Q3 2026 Earnings Call Transcript
The Motley Fool · 11/10 01:00
Atea Pharmaceuticals Q3 2026 Earnings Call Transcript
Benzinga · 11/09 22:27
Atea Pharmaceuticals GAAP EPS of -$0.40 beats by $0.02
Seeking Alpha · 11/09 21:44
*Atea Pharmaceuticals 3Q Loss/Shr 40c >AVIR
Dow Jones · 11/09 21:10
Press Release: Atea Pharmaceuticals Reports Third -2-
Dow Jones · 11/09 21:05
Press Release: Atea Pharmaceuticals Reports Third -3-
Dow Jones · 11/09 21:05
Atea Secures $200 Mln Credit Facility From Hercules Capital; Shares Up
NASDAQ · 11/09 20:44
Atea Pharmaceuticals, Inc. Enters into $200.0 million Loan and Security Agreement
NASDAQ · 11/09 17:11
Here are the major earnings after the close Monday
Seeking Alpha · 11/09 15:00
Atea Pharmaceuticals Secures Up to $200 Million in Financing
TipRanks · 11/09 13:01
Press Release: Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
Dow Jones · 11/09 12:00
Press Release: Atea Pharmaceuticals Secures -2-
Dow Jones · 11/09 12:00
More
Webull provides a variety of real-time AVIR stock news. You can receive the latest news about Atea Pharmaceuticals, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About AVIR
Atea Pharmaceuticals, Inc. is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Its product candidate pipeline includes the regimen of bemnifosbuvir and ruzasvir which has the potential to improve the current standard of care (SOC) for the treatment of patients with hepatitis C virus (HCV) infection and AT-587 which has the potential to be the first direct-acting antiviral (DAA) for the treatment of patients, particularly immunocompromised patients, with chronic hepatitis E virus (HEV) infection. The global HCV Phase III program it is conducting consists of two randomized, open-label studies: C-BEYOND which has clinical trial sites in the United States and Canada, and C-FORWARD which has clinical trial sites in countries outside of North America. AT-587 has demonstrated potent nanomolar antiviral activity against HEV in vitro.